{"id":51838,"date":"2026-03-20T13:44:00","date_gmt":"2026-03-20T06:44:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=51838"},"modified":"2026-03-20T13:44:00","modified_gmt":"2026-03-20T06:44:00","slug":"ribo-expands-beyond-the-liver-with-ribopepstar-enabling-targeted-sirna-delivery-to-multiple-organs","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=51838","title":{"rendered":"Ribo expands beyond the liver with RiboPepSTAR\u2122 – enabling targeted siRNA delivery to multiple organs"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SUZHOU, China and M\u00d6LNDAL, Sweden<\/span>, March 20, 2026<\/span> \/PRNewswire\/ — Suzhou Ribo Life Science Co., Ltd.\u00a0 (“Ribo” or “the Company”, Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.\u00a0<\/p>\n

\n<\/div>\n

Following the success of RiboGalSTAR\u2122, which has supported seven clinical programs and major global partnerships valued over USD 6 billion, Ribo is now advancing its extra hepatic and multi-target platforms. The proprietary RiboPepSTAR\u2122 technology enables precise siRNA delivery to key organs beyond the liver, with promising preclinical data across several tissues.\u00a0<\/p>\n

Kidney targeting\u00a0<\/b><\/p>\n

Using RiboPepSTAR\u2122, preclinical studies demonstrate selective uptake in proximal tubular cells across models, and up to 80% target gene knockdown (KD) has been achieved, from rodents to NHPs. Physiological proof of concept was further validated in several disease models, such as type 2 diabetes model, showing robust kidney specific target-related biomarker reduction. Ribo’s first kidney-targeted drug has entered IND-enabling phase.\u00a0<\/p>\n

Cardiac targeting\u00a0<\/b><\/p>\n

A cardiac targeting conjugate resulted in sustained knockdown in heart using a mouse model. Minimal effects were observed in muscle and negligible activity in liver and kidney, confirming strong cardiac specificity.\u00a0<\/p>\n

Adipose tissue targeting\u00a0<\/b><\/p>\n

In NHPs, current delivery enabled potent and selective adipose targeting with 96% knockdown.\u00a0<\/p>\n

Together, these results underscore RiboPepSTAR\u2122’s potential to unlock siRNA-based therapies for renal, cardiac and metabolic diseases.\u00a0<\/p>\n

In parallel, Ribo is advancing its multi target siRNA platform, enabling a single molecule to silence two or more genes simultaneously. Ribo’s dual target siRNAs achieve knockdown levels comparable to single target molecules, enabling synergistic pathway modulation and enhanced therapeutic benefit with a single therapeutic entity.\u00a0<\/p>\n

Ribo’s proprietary extra hepatic and multi targeting platforms open the door to best-in-class therapies across a broad range of disease areas – fully aligned with Ribo’s commitment to delivering next generation siRNA medicines to patients worldwide.\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SUZHOU, China and M\u00d6LNDAL, Sweden<\/span>, March 20, 2026<\/span> \/PRNewswire\/ — Suzhou Ribo Life Science Co., Ltd.\u00a0 (“Ribo” or “the Company”, Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.\u00a0<\/p>\n

\n<\/div>\n

Following the success of RiboGalSTAR\u2122, which has supported seven clinical programs and major global partnerships valued over USD 6 billion, Ribo is now advancing its extra hepatic and multi-target platforms. The proprietary RiboPepSTAR\u2122 technology enables precise siRNA delivery to key organs beyond the liver, with promising preclinical data across several tissues.\u00a0<\/p>\n

Kidney targeting\u00a0<\/b><\/p>\n

Using RiboPepSTAR\u2122, preclinical studies demonstrate selective uptake in proximal tubular cells across models, and up to 80% target gene knockdown (KD) has been achieved, from rodents to NHPs. Physiological proof of concept was further validated in several disease models, such as type 2 diabetes model, showing robust kidney specific target-related biomarker reduction. Ribo’s first kidney-targeted drug has entered IND-enabling phase.\u00a0<\/p>\n

Cardiac targeting\u00a0<\/b><\/p>\n

A cardiac targeting conjugate resulted in sustained knockdown in heart using a mouse model. Minimal effects were observed in muscle and negligible activity in liver and kidney, confirming strong cardiac specificity.\u00a0<\/p>\n

Adipose tissue targeting\u00a0<\/b><\/p>\n

In NHPs, current delivery enabled potent and selective adipose targeting with 96% knockdown.\u00a0<\/p>\n

Together, these results underscore RiboPepSTAR\u2122’s potential to unlock siRNA-based therapies for renal, cardiac and metabolic diseases.\u00a0<\/p>\n

In parallel, Ribo is advancing its multi target siRNA platform, enabling a single molecule to silence two or more genes simultaneously. Ribo’s dual target siRNAs achieve knockdown levels comparable to single target molecules, enabling synergistic pathway modulation and enhanced therapeutic benefit with a single therapeutic entity.\u00a0<\/p>\n

Ribo’s proprietary extra hepatic and multi targeting platforms open the door to best-in-class therapies across a broad range of disease areas – fully aligned with Ribo’s commitment to delivering next generation siRNA medicines to patients worldwide.\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-51838","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/51838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51838"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/51838\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}